New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
11:18 EDTABBV, JNJAbbVie patents affirmed as invalid by appeals court in suit with J&J unit
An appeals court affirmed a lower court finding that AbbVie (ABBV) patents involving antibodies that are useful for treating diseases are invalid. AbbVie has sued Janssen Biotech, a unit of Johnson & Johnson (JNJ), and Centocor Biologics for infringement of the patent claims. Reference Link
News For ABBV;JNJ From The Last 14 Days
Check below for free stories on ABBV;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
11:41 EDTJNJCubist rises after report sparks takeover interest speculation
Subscribe for More Information
August 12, 2014
09:35 EDTJNJActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GOOG C TSL EXAS BAC DNDN JNJ TSLA
August 8, 2014
09:01 EDTJNJJohnson & Johnson remains undervalued, says Cowen
Subscribe for More Information
07:48 EDTABBVCredit Suisse remains a buyer of AbbVie
Subscribe for More Information
August 6, 2014
12:59 EDTABBVCovidien drops as Treasury explores ways to stymie inversions
Shares of medical device and drug maker Covidien (COV) are falling after multiple media outlets reported that the Treasury Department is looking into ways of curtailing tax inversion deals. Covidien has agreed to be acquired by Medtronic (MDT) in a tax inversion deal. BACKGROUND: Tax inversions refer to an acquisition of one company, usually officially based in a country in Europe or elsewhere, by a U.S. company, following which the acquiring company becomes domiciled in the same country as the company that it bought. The switch has the potential to significantly lower the acquiring company's tax rate. WHAT'S NEW: The Treasury Department is looking at options that would enable the Obama administration to curtail inversion deals without authorization from Congress, multiple media outlets reported last night and today. ANALYST REACTION: In a note to investors today, Wells Fargo analyst Larry Biegelsen wrote that he believes that Medtronic would buy Covidien even if the transaction cannot be done as an inversion. At a conference in June, Medtronic CFO Gary Ellis said that his company would "do the deal whether it's an inversion or not inversion," Biegelsen stated. If no inversion is possible, Medtronic would respond by using less of its stock and more debt to fund the transaction, the analyst believes. Such a change would actually cause Medtronic's cash earnings per share to be higher in the first and second year after the deal than under the current structure, the analyst indicated. He kept an Outperform rating on Medtronic. PRICE ACTION: In early afternoon trading, Covidien dropped 2% to $84.50 and Medtronic fell 1% to $61.50. Meanwhile, drug maker Shire (SHPG), which has agreed to merge with its peer AbbVie (ABBV) in a tax inversion deal, is falling 4% to $236.
08:40 EDTABBVShire drops 5% with tax inversions in focus
Subscribe for More Information
06:21 EDTJNJPiper Jaffray to hold a summit
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use